Search results
17 lip 2023 · Full results about the Alzheimer's disease drug donanemab have been released today, supporting earlier trial results that suggested the breakthrough drug may slow down the progression of the disease.
11 cze 2024 · 01:48 - Source: CNN. CNN — On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow...
17 lip 2023 · Promising preliminary results from a trial of the Alzheimer’s drug donanemab, first announced in May, have now been confirmed. The full results were made public today at the Alzheimer’s Association International Conference by the pharmaceutical company Eli Lilly, which manufactures the drug.
17 lip 2023 · A new drug, donanemab, is being hailed as a turning point in the fight against Alzheimer's, after a global trial confirms it slows cognitive decline. The antibody medicine helps in the early...
2 lip 2024 · The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
2 lip 2024 · CHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
3 maj 2023 · The drug manufacturer Eli Lilly announced on Wednesday that a clinical trial of an experimental Alzheimer’s drug showed it can slow progress of the feared disease and allow patients to have...
